These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38767062)

  • 1. piSTING: A Pocket-Independent Agonist Based on Multivalency-Driven STING Oligomerization.
    Zhuo SH; Wang TY; Zhao L; Su JY; Hu JJ; Zhao YF; Li YM
    Angew Chem Int Ed Engl; 2024 Sep; 63(38):e202407037. PubMed ID: 38767062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
    Xie X; Liu J; Wang X
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged activation of innate immune pathways by a polyvalent STING agonist.
    Li S; Luo M; Wang Z; Feng Q; Wilhelm J; Wang X; Li W; Wang J; Cholka A; Fu YX; Sumer BD; Yu H; Gao J
    Nat Biomed Eng; 2021 May; 5(5):455-466. PubMed ID: 33558734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2',4'-LNA-Functionalized 5'-S-Phosphorothioester CDNs as STING Agonists.
    Yeboah SK; Zigli A; Sintim HO
    Chembiochem; 2024 Jul; 25(13):e202400321. PubMed ID: 38720428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
    Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
    Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth.
    Shaji SG; Patel P; Mamani UF; Guo Y; Koirala S; Lin CY; Alahmari M; Omoscharka E; Cheng K
    Int J Nanomedicine; 2024; 19():8769-8778. PubMed ID: 39220196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
    Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
    J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic.
    Chin EN; Yu C; Vartabedian VF; Jia Y; Kumar M; Gamo AM; Vernier W; Ali SH; Kissai M; Lazar DC; Nguyen N; Pereira LE; Benish B; Woods AK; Joseph SB; Chu A; Johnson KA; Sander PN; Martínez-Peña F; Hampton EN; Young TS; Wolan DW; Chatterjee AK; Schultz PG; Petrassi HM; Teijaro JR; Lairson LL
    Science; 2020 Aug; 369(6506):993-999. PubMed ID: 32820126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING-induced regulatory B cells compromise NK function in cancer immunity.
    Li S; Mirlekar B; Johnson BM; Brickey WJ; Wrobel JA; Yang N; Song D; Entwistle S; Tan X; Deng M; Cui Y; Li W; Vincent BG; Gale M; Pylayeva-Gupta Y; Ting JP
    Nature; 2022 Oct; 610(7931):373-380. PubMed ID: 36198789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles.
    Li X; Khorsandi S; Wang Y; Santelli J; Huntoon K; Nguyen N; Yang M; Lee D; Lu Y; Gao R; Kim BYS; de Gracia Lux C; Mattrey RF; Jiang W; Lux J
    Nat Nanotechnol; 2022 Aug; 17(8):891-899. PubMed ID: 35637356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
    Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
    J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING activation in cancer immunotherapy.
    Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
    Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
    Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
    J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of small molecule inhibitors/agonists targeting STING for disease.
    Liu K; Lan Y; Li X; Li M; Cui L; Luo H; Luo L
    Biomed Pharmacother; 2020 Dec; 132():110945. PubMed ID: 33254439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
    Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
    Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment.
    Wang Z; Miao F; Gu L; Zhang R; Ma Y; Li Y; Zheng J; Lin Z; Gao Y; Huang L; Shen Y; Wu T; Luo F; Li W
    ACS Nano; 2024 Sep; 18(35):24219-24235. PubMed ID: 39172516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.